Sorokin, M.
Ignatev, K.
Barbara, V.
Vladimirova, U.
Muraveva, A.
Suntsova, M.
Gaifullin, N.
Vorotnikov, I.
Kamashev, D.
Bondarenko, A.
Baranova, M.
Poddubskaya, E.
Buzdin, A.
Article History
Received: 31 March 2020
Revised: 29 May 2020
Accepted: 31 May 2020
First Online: 24 June 2020
Ethics declarations
: For all the biosamples, informed written consents were collected from the patients to participate in the clinical trial NCT03521245 “Molecular pathway activation markers predicting efficacy of trastuzumab therapy for HER2-positive breast cancer” and to communicate the results in this report. All procedures performed in studies involving human participants were in accordance with the ethical standards of the Karelia Republic Oncological Hospital, Petrozavodsk, and the Vitamed Oncological Clinical Center, Moscow.
: The authors M. Sorokin and A. Buzdin were employed by the company OmicsWay Corp. The authors declare that this study received funding from OmicsWay Corp. The funder had the following involvement in the study: data analysis and interpretation as well as the writing of this manuscript. The funder was not involved in the study design, collection of data, decision to submit this article for publication. The remaining authors declare no conflict of interest in financial or any other sphere.